{
  "catalysts": [
    {
      "ticker": "OCUL",
      "current_price": 8.88,
      "market_cap": "$1.93B",
      "conviction_score": 9,
      "thesis": "Critical Phase 3 SOL-1 topline data for AXPAXLI (wet AMD) due Feb 17; 'single biggest biotech catalyst of the week' with potential acquisition interest from Sanofi if positive.",
      "catalyst_details": "Company confirmed on Feb 13 that topline Phase 3 data will be presented via webcast on Tuesday, Feb 17 at 8:00 AM ET.",
      "absorption_status": "Unpriced Anticipation. Stock closed down 2% on Friday amidst broad market weakness, offering a discount before the binary event.",
      "earnings_date": "N/A (Data Readout)",
      "relative_volume": "0.6x (Volume 2.65M vs Avg 5.16M)",
      "stop_loss_trigger": "$8.26",
      "sentiment": "Bullish",
      "prediction_market": "High Volatility Expected (Implied move >20%)",
      "recency_proof": "GlobeNewswire (Feb 13, 2026) - Webcast Announcement",
      "risk": "Binary Event Failure (Data miss would severely impact stock)",
      "expected_upside": "30-50% on positive superiority data",
      "mispricing_evidence": "Stock is trading significantly below analyst targets ($22.56 avg) despite approaching pivotal de-risking event.",
      "x_sentiment": "High anticipation for 'superiority' designation.",
      "hold_time_estimate": "2-3 Days",
      "atr_value": 0.63,
      "calculated_stop_loss": 8.26,
      "breakeven_trigger": 9.81,
      "shares_count": 11.2613,
      "position_cost": 100.0,
      "risk_r_unit": 0.62
    },
    {
      "ticker": "PSNL",
      "current_price": 8.21,
      "market_cap": "$729M",
      "conviction_score": 8,
      "thesis": "Major shareholder Tempus AI (10% Owner) aggressively accumulated ~$2.7M worth of shares between Feb 11-13, signaling strong undervaluation confidence.",
      "catalyst_details": "SEC Form 4 filed Feb 13, 2026, disclosing purchase of 320,267 shares at prices ~$8.55-$9.00.",
      "absorption_status": "Unpriced. Filing dropped after market close Friday; After-hours price rose 4% to $8.55.",
      "earnings_date": "2026-02-26",
      "relative_volume": "Low (Volume fell on pullback, bullish divergence)",
      "stop_loss_trigger": "$7.64",
      "sentiment": "Bullish",
      "prediction_market": "N/A",
      "recency_proof": "SEC Form 4 Filing (Feb 13, 2026)",
      "risk": "Illiquidity / High Beta",
      "expected_upside": "20-30% (Revisit recent highs of $11.50)",
      "mispricing_evidence": "Insider buying at prices above current close ($8.55 avg buy vs $8.21 close).",
      "x_sentiment": "Positive chatter on insider accumulation.",
      "hold_time_estimate": "2-4 Weeks",
      "atr_value": 0.79,
      "calculated_stop_loss": 7.64,
      "breakeven_trigger": 9.07,
      "shares_count": 12.1803,
      "position_cost": 100.0,
      "risk_r_unit": 0.57
    }
  ]
}